Medications

Dexamethasone still beneficial for some inpatients with COVID-19

Early administration of dexamethasone is associated with significantly reduced odds of mortality or discharge to hospice for inpatients with COVID-19 receiving supplemental oxygen or mechanical ventilation (MV) and/or extracorporeal ...

Medications

Survival benefit seen with triple therapy for severe COVID-19

For patients with severe COVID-19 requiring high flow nasal cannula (HFNC), triple therapy of dexamethasone, remdesivir, and baricitinib is associated with significant survival benefit compared with dual therapy, according ...

Medications

Study compares baricitinib to dexamethasone for COVID-19

For hospitalized patients with COVID-19 requiring supplemental oxygen, baricitinib plus remdesivir and dexamethasone plus remdesivir result in similar mechanical ventilation-free survival by day 29, but adverse events occur ...

Medications

COVID-19 therapies are better in combination than alone

There is a steadily growing arsenal of drugs for COVID-19. Researchers from Charité-Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC) and Freie Universität (FU) Berlin have studied the mechanisms ...

Diseases, Conditions, Syndromes

Higher dose of steroid does not improve outcomes in severe COVID-19

(HealthDay)—The number of days alive without life support at day 28 did not differ among adults with COVID-19 and severe hypoxemia receiving dexamethasone 12 mg/day versus dexamethasone 6 mg/day administered intravenously ...

Oncology & Cancer

Anti-nausea drug may help some cancer patients survive longer

Patients with breast, pancreatic and certain other types of cancer may survive longer if given an anti-nausea drug during surgery, according to a large study being presented at the ANESTHESIOLOGY 2021 annual meeting. Three ...

page 2 from 8